Fibrocell Announces Submission of Investigational New Drug Application for FCX-013

Fibrocell Science (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the submission of an Investigational New Drug Application with the U.S. Food and Drug Administration for FCX-013, the Company’s gene therapy candidate for the treatment of moderate to severe localized scleroderma.

As quoted in the press release:

Localized scleroderma is a chronic autoimmune skin disorder that manifests as excess production of collagen resulting in thickening, or fibrosis, of the skin and connective tissue. Moderate to severe forms of localized scleroderma, including the linear subtype, can result in significant morbidity, including pain, restricted motion, disfigurement and developmental issues.

Click here to read the full press release.